Study of the role of connexin 26 in metastasis of malignant melanoma and development of metastasis inhibitor
Project/Area Number |
20591325
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Dermatology
|
Research Institution | Nara Medical University |
Principal Investigator |
ASADA Hideo Nara Medical University, 医学部, 教授 (60252681)
|
Co-Investigator(Renkei-kenkyūsha) |
ITO Akihiko 近畿大学, 医学部, 教授 (80273647)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 悪性黒色腫 / コネキシン26 / ギャップ結合 / 転移 / 内皮細胞 |
Research Abstract |
Malignant melanoma is a tumor of the poor prognosis in which the metastasis is caused at the early stage. We previously found that connexin 26 (Cx26) took an important role in the metastasis of malignant melanoma. I aimed at the development of a molecular target medicine controlling the metastasis of malignant melanoma in this study, and tried making the antibodies for the extracellular domains of the Cx26 molecule, and examined the metastasis controlling effect of the antibodies using a malignant melanoma metastasis mouse model. As a result, the antibodies showed metastasis control action although it was not strong.
|
Report
(4 results)
Research Products
(17 results)
-
[Journal Article] Repair pathways independent of the Fanconi anemia nuclear core complex play a predominant role in mitigating formaldehyde-induced DNA damage.2011
Author(s)
Noda T, Takahashi A, Kondo N, Mori E, Okamoto N, Nakagawa Y, Ohnishi K, Zdzienicka MZ, Thompson LH, Helleday T, Asada H, Ohnishi T
-
Journal Title
Biochem Biophys Res Commun 404
Pages: 206-210
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-